Protalix Biotherapeutics (NYSEAMERICAN:PLX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Saturday.

According to Zacks, “Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. “

How to Become a New Pot Stock Millionaire

Other equities analysts have also recently issued reports about the stock. HC Wainwright set a $5.00 target price on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Wednesday, November 29th. BidaskClub cut shares of Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd.

Protalix Biotherapeutics (NYSEAMERICAN PLX) opened at $0.69 on Friday. The company has a market cap of $329.82, a P/E ratio of -0.34 and a beta of 0.97. Protalix Biotherapeutics has a 12-month low of $0.48 and a 12-month high of $1.51.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last issued its earnings results on Tuesday, March 6th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $2.47 million for the quarter, compared to the consensus estimate of $9.70 million.

An institutional investor recently bought a new position in Protalix Biotherapeutics stock. Opaleye Management Inc. acquired a new position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,825,000 shares of the company’s stock, valued at approximately $1,206,000. Opaleye Management Inc. owned approximately 1.27% of Protalix Biotherapeutics at the end of the most recent reporting period.

COPYRIGHT VIOLATION NOTICE: “Protalix Biotherapeutics (PLX) Downgraded to Sell at Zacks Investment Research” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/03/12/protalix-biotherapeutics-plx-downgraded-to-sell-at-zacks-investment-research.html.

Protalix Biotherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Get a free copy of the Zacks research report on Protalix Biotherapeutics (PLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.